Literature DB >> 21668626

Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques.

C Lefaucheur1, C Antoine, C Suberbielle, D Glotz.   

Abstract

The utilization of sensitive techniques of detection of HLA antibodies to define and measure sensitization has greatly evolved in recent years. We present here an approach to minimize the risk of HLA antibodies in kidney transplantation based on the evaluation of graft accessibility of sensitized patients by calculated PRA (cPRA) and estimation of potential matched donors (PMD) using a national simulation software program. This study included all registered patients on our waiting list (WL) for deceased donor (DD) kidney transplants. All patients were screened by single-antigen flow bead (SAFB) techniques. Of the 502 registered patients, 174 (34.7%) were sensitized. Among these, 48.3% (84 pts) had a cPRA>85%. For 75.3% of sensitized patients (90 pts with cPRA≤85% and 41 pts with cPRA>85%), the flow of PMD was considered sufficient to allow a transplant avoiding all unacceptable antigens. The 41 patients with a cPRA>85% (48.8%) had a satisfactory donor flow in the framework of the national prioritization program for highly sensitized patients. Finally, 43 sensitized patients (24.7%) were deemed eligible for a strategy of higher immunological risk through desensitization protocols or transplantation against HLA-DSAs. This approach provides a logical and systematic strategy to rationalize the access of sensitized patients to kidney transplantation minimizing the risk of HLA antibodies. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668626     DOI: 10.1111/j.1600-6143.2011.03560.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  5 in total

1.  Banff 2011 Meeting report: new concepts in antibody-mediated rejection.

Authors:  M Mengel; B Sis; M Haas; R B Colvin; P F Halloran; L C Racusen; K Solez; L Cendales; A J Demetris; C B Drachenberg; C F Farver; E R Rodriguez; W D Wallace; D Glotz
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

Review 2.  Identification and therapeutic management of highly sensitized patients undergoing renal transplantation.

Authors:  Lu Huber; Nils Lachmann; Michael Dürr; Mareen Matz; Lutz Liefeldt; Hans-H Neumayer; Constanze Schönemann; Klemens Budde
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 3.  Diagnosis and management of antibody-mediated rejection: current status and novel approaches.

Authors:  A Djamali; D B Kaufman; T M Ellis; W Zhong; A Matas; M Samaniego
Journal:  Am J Transplant       Date:  2014-01-08       Impact factor: 8.086

4.  HLA Desensitization Based on Results of the Luminex Technique in Kidney Transplant - A Single-center Experience.

Authors:  S B Bansal; A Gade; S Sinha; A Mahapatra; P Jha; S K Sethi
Journal:  Indian J Nephrol       Date:  2021-04-02

5.  Allogenicity & immunogenicity in regenerative stem cell therapy.

Authors:  Dominique Charron
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.